Form 4: Myriad Genetics Officer Reports Stock Transaction

Brian J. Donnelly, Chief Commercial Officer of Myriad Genetics Inc., reported a transaction involving the withholding of common stock to cover tax obligations.

Summary

• Brian J. Donnelly, Chief Commercial Officer of Myriad Genetics Inc. (MYGN), reported a transaction on May 1, 2026.
• The transaction involved the withholding of 55,975 shares of common stock by the Issuer to satisfy tax withholding obligations.
• These shares were withheld in connection with the vesting of previously granted restricted stock units.
• The number of shares withheld was based on the closing price of Myriad Genetics' common stock on May 1, 2026, which was $4.80 per share.
• Following this transaction, Mr. Donnelly beneficially owns 568,363 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine administrative transaction related to executive compensation rather than a strategic business development or financial performance indicator.

Positives

• The transaction reflects the settlement of vested restricted stock units, indicating the fulfillment of prior compensation awards.
• Direct beneficial ownership of 568,363 shares by a key executive suggests continued commitment to the company.

Negatives

• The withholding of shares for tax purposes, while standard, represents a reduction in the immediate number of shares available to the reporting person.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future company performance.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for publicly traded companies, detailing changes in beneficial ownership by insiders. This specific filing from Myriad Genetics (MYGN) is a standard report of an executive settling tax obligations related to vested equity compensation, a common practice in the biotechnology and healthcare sectors.

Stakeholder Impact

• Shareholders: The transaction does not directly impact the total number of outstanding shares but reflects the standard compensation mechanism for executives.
• Employees: This filing is specific to an executive's compensation and does not directly affect other employees.
• Management: Brian J. Donnelly, as Chief Commercial Officer, continues to hold a significant direct beneficial ownership in the company.

Key Dates

Keywords

Myriad Genetics, MYGN, Form 4, Insider Transaction, Stock Withholding, Restricted Stock Units, Executive Compensation, Beneficial Ownership